Godavari Bioref.

Which are the latest news on Godavari Bioref.?

Why is Godavari Biorefineries Ltd falling/rising?

As of 05-Sep, Godavari Biorefineries Ltd's stock price is at 242.05, down 1.24%, following a trend reversal after three days of gains. Despite a recent increase in investor participation, the stock has underperformed over various time frames and remains below longer-term moving averages, indicating a lack of sustained upward momentum.

As of 05-Sep, Godavari Biorefineries Ltd's stock price is falling, currently at 242.05, down by 3.05 or 1.24%. This decline follows a trend reversal after three consecutive days of gains. Additionally, the stock has underperformed over various time frames, with a year-to-date decrease of 13.09% compared to a 10.21% drop in the benchmark Sensex. Over the past month, the stock has decreased by 7.54%, while the Sensex fell by 2.44%. <BR><BR>Today's performance indicates that the stock has outperformed its sector by 0.56%, but the overall trend in the sugar sector has been negative, with a decline of 2.2%. Furthermore, while there has been a notable increase in investor participation, with delivery volume rising by 219.04% against the 5-day average, the stock remains below its longer-term moving averages, which may indicate a lack of sustained upward momentum. Overall, these factors contribute to the current decline in the stock price of Godavari Biorefineries Ltd.

What does Godavari Bioref. do?

Godavari Biorefineries Ltd, a micro-cap company in the FMCG industry, reported net sales of 558 Cr and a net loss of 19 Cr for June 2026. It was founded in 1956 and renamed in 2006, with a market cap of INR 1,206 Cr.

Overview:<BR>Godavari Biorefineries Ltd operates in the FMCG industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated as 'Godavari Investment and Finance Corporation Limited' in 1956. It later changed its name to 'Godavari Biorefineries Limited' in 2006. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 558 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: -19 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 1,206 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 41.00 <BR>Industry P/E: 23 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.63 <BR>Return on Equity: 4.12% <BR>Price to Book: 1.56 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Godavari Bioref.?

Godavari Bioref.'s peers include Eveready Inds., Venky's (India), SKM Egg Prod., and others, with varying management and growth risks. Its 1-year return is -6.27%, better than Eveready Inds. (-21.70%) but worse than Apex Frozen Food (79.45%).

Peers: The peers of Godavari Bioref. are Eveready Inds., Venky's (India), SKM Egg Prod., Andrew Yule & Co, Apex Frozen Food, HMA Agro Inds., Jindal Photo, Anondita Medi., and Freshara Agro.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anondita Medi., while Average management risk is found at Eveready Inds., Venky's (India), SKM Egg Prod., Apex Frozen Food, HMA Agro Inds., and Jindal Photo, and the rest. Below Average management risk is noted for Andrew Yule & Co and Godavari Bioref. In terms of Growth, Excellent growth is seen at Anondita Medi. and SKM Egg Prod., while Average growth is found at Eveready Inds., Venky's (India), Apex Frozen Food, HMA Agro Inds., and Jindal Photo, and the rest. Below Average growth is noted for Andrew Yule & Co and Godavari Bioref. Regarding Capital Structure, Excellent capital structure is observed at Venky's (India) and Anondita Medi., Good capital structure is found at SKM Egg Prod. and Apex Frozen Food, while Average capital structure is noted for Eveready Inds., HMA Agro Inds., and the rest, and Below Average capital structure is seen at Andrew Yule & Co, Godavari Bioref., and Jindal Photo.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Apex Frozen Food at 79.45%, while the peer with the lowest is Eveready Inds. at -21.70%. Godavari Bioref.'s 1-year return is -6.27%, which is better than Eveready Inds. but worse than Apex Frozen Food. Additionally, HMA Agro Inds. and Jindal Photo have negative six-month returns.

How big is Godavari Bioref.?

As of 31st August, Godavari Biorefineries Ltd has a market capitalization of 1,206.00 Cr, with net sales of 2,012.58 Cr and a net profit of 0.22 Cr reported in the latest four quarters. The company has shareholder's funds of 781.96 Cr and total assets of 1,955.09 Cr as of March 2025.

As of 31st August, Godavari Biorefineries Ltd has a market capitalization of 1,206.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Godavari Biorefineries reported net sales of 2,012.58 Cr and a net profit of 0.22 Cr.<BR><BR>For the latest annual period ending in March 2025, the company had shareholder's funds amounting to 781.96 Cr and total assets of 1,955.09 Cr.

Should I buy, sell or hold Godavari Biorefineries Ltd?

When is the next results date for Godavari Biorefineries Ltd?

The next results date for Godavari Biorefineries Ltd is August 5, 2026.

The next results date for Godavari Biorefineries Ltd is scheduled for August 5, 2026.

Are Godavari Biorefineries Ltd latest results good or bad?

Godavari Biorefineries Ltd's latest results show a strong quarter-on-quarter recovery with a net profit increase of 540.97% and a revenue rise of 22.67%. However, year-on-year comparisons reveal a 26.48% drop in net profit and a 2.66% decline in revenue, indicating concerns about long-term growth sustainability.

The latest results for Godavari Biorefineries Ltd show a mixed picture. On one hand, the company reported a significant recovery in Q4 FY26, with a net profit of ₹52.88 crore, marking an impressive 540.97% increase quarter-on-quarter. Revenue also rose by 22.67% to ₹564.10 crore compared to the previous quarter. Additionally, operating margins improved to 15.28%, reflecting better pricing power and operational efficiency.<BR><BR>However, when looking at year-on-year performance, the results are less favorable. The net profit decreased by 26.48% from ₹71.93 crore in Q4 FY25, and revenue fell by 2.66% from ₹579.50 crore in the same quarter last year. This highlights a struggle to maintain consistent growth across fiscal years.<BR><BR>Overall, while the sequential recovery is a positive sign, the year-on-year declines raise concerns about the sustainability of this performance. Investors should be cautious, as the company's financial history has shown significant volatility, swinging from losses to profits, which complicates the outlook for future earnings stability.

Is Godavari Bioref. technically bullish or bearish?

As of December 1, 2025, the market trend has shifted to sideways with neutral indicators, as the weekly MACD and Bollinger Bands are bearish, while daily moving averages are mildly bullish but lack strong momentum.

As of 1 December 2025, the technical trend has changed from mildly bullish to sideways. The current stance is neutral, with weak indicators supporting this position. The weekly MACD is bearish, and Bollinger Bands also indicate a bearish trend. The daily moving averages are mildly bullish, but this is offset by the lack of signals from the RSI and the KST being mildly bearish. Additionally, Dow Theory shows no trend in both weekly and monthly time frames. Overall, the indicators suggest a lack of strong momentum in either direction.

How has been the historical performance of Godavari Bioref.?

Godavari Bioref. has faced significant fluctuations in financial performance, with net sales decreasing from 2,014.69 crore in March 2023 to 1,870.25 crore in March 2025, and profitability declining sharply, resulting in a profit after tax of -23.41 crore in March 2025. The company has struggled with rising expenditures and a notable drop in cash flow from operations.

Answer:<BR>The historical performance of Godavari Bioref. has shown significant fluctuations over the years, particularly in its net sales and profitability.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2025, Godavari Bioref. reported net sales of 1,870.25 crore, an increase from 1,686.67 crore in March 2024 but a decrease from 2,014.69 crore in March 2023. The total operating income mirrored this trend, reaching 1,870.25 crore in March 2025. The company's total expenditure, excluding depreciation, rose to 1,766.60 crore in March 2025 from 1,553.13 crore in March 2024, leading to an operating profit (PBDIT) of 120.31 crore, down from 147.94 crore the previous year. This decline in profitability is reflected in the profit before tax, which fell to -1.54 crore in March 2025 from 12.45 crore in March 2024, resulting in a profit after tax of -23.41 crore compared to 12.30 crore in the prior year. The company's total assets decreased slightly to 1,955.09 crore in March 2025 from 1,991.50 crore in March 2024, while total liabilities also saw a decline to 1,955.09 crore from 1,991.50 crore. Cash flow from operating activities dropped significantly to 6.00 crore in March 2025 from 185.00 crore in March 2024, indicating challenges in generating cash from core operations. Overall, Godavari Bioref. has experienced a challenging financial environment, marked by declining profits and fluctuating sales.

Is Godavari Bioref. overvalued or undervalued?

As of May 26, 2025, Godavari Bioref. is considered overvalued with a valuation grade of "attractive," reflected in its negative PE ratio of -53.80, high EV to EBITDA of 20.92, and low ROCE of 4.46%, especially when compared to peers like E.I.D.-Parry and Balrampur Chini Mills.

As of 26 May 2025, the valuation grade for Godavari Bioref. has moved from very attractive to attractive. The company appears to be overvalued based on its current financial metrics. Key ratios include a PE ratio of -53.80, an EV to EBITDA of 20.92, and a ROCE of 4.46%. In comparison, E.I.D.-Parry (India) Ltd. has a PE ratio of 27.55 and an EV to EBITDA of 5.63, while Balrampur Chini Mills Ltd. shows a PE of 28.14 and an EV to EBITDA of 21.19, indicating that Godavari Bioref. is trading at a significant premium relative to its peers.<BR><BR>The company's financials reflect challenges, particularly with a negative ROE of -5.49% and a PEG ratio of 0.00, suggesting limited growth prospects. While the stock has performed well recently, with a 1-month return of 74.99% compared to the Sensex's 3.80%, this may not be sustainable given the underlying valuation metrics. Overall, the analysis indicates that Godavari Bioref. is overvalued in the current market context.

Who are the top shareholders of the Godavari Bioref.?

The top shareholders of Godavari Bioref. include Somaiya Agencies Private Limited with 17.3%, mutual funds holding 10.95% (led by HDFC Mutual Fund at 4.1%), and individual investors at 17.64%. There are also eight foreign institutional investors with a combined 0.97%, and no pledged promoter holdings are reported.

The top shareholders of Godavari Bioref. include a mix of promoters, mutual funds, and individual investors. The majority shareholder is Somaiya Agencies Private Limited, which holds 17.3% of the company. Additionally, mutual funds collectively hold 10.95% across six schemes, with HDFC Mutual Fund - HDFC Manufacturing Fund being the highest public shareholder at 4.1%. Individual investors account for 17.64% of the holdings. There are also eight foreign institutional investors (FIIs) holding a small portion of 0.97%. Notably, there are no pledged promoter holdings reported.

Has Godavari Bioref. declared dividend?

No Dividend History Available